TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: A case series and review of the literature

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages 129-137

  Hatemi, Ibrahim ^a   Hatemi, Gulen ^a   Pamuk, Omer Nuri ^b   Erzin, Yusuf ^a   Celik, Aykut Ferhat ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b TRAKYA UNIVERSITY   (Turkey)

Author keywords

Adalimumab; Beh et's disease; Beh et's syndrome; Etanercept; Inflammatory bowel disease; Infliximab; Intestinal involvement; Management; Thalidomide

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; 5 ACETAMIDOSALICYLIC ACID DERIVATIVE; ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CANAKINUMAB; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; BEHCET DISEASE; CASE STUDY; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; COLONOSCOPY; DEMOGRAPHY; DISEASE DURATION; FEMALE; GASTROINTESTINAL BEHCET SYNDROME; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEMICOLECTOMY; HUMAN; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; PRIORITY JOURNAL; REMISSION; SEPSIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; BEHCET SYNDROME; COMPLICATION; GASTROINTESTINAL DISEASES; IMMUNOLOGY; INFANT; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BEHCET SYNDROME; BIOLOGICAL PRODUCTS; CHILD; CHILD, PRESCHOOL; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; MIDDLE AGED; REMISSION INDUCTION; THALIDOMIDE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84954621530     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. CHEON JH, CELIK AF, KIM WH: Behçet's Disease: Gastrointestinal involvement. In YAZICI Y, YAZICI H (Eds.) Behçet's syndrome. New York, Springer; 2010: 165-89.
2. CHOI IJ, KIM JS, CHA SD et al.: Long-term clinical course and prognostic factors in intestinal Behçet's disease. Dis Colon Rectum 2000; 43: 692-700.
3. YURDAKUL S, YAZICI Y: Epidemiology of Behçet's syndrome and regional differences in disease expression. In: YAZICI Y, YAZICI H, editors. Behçet's syndrome. New York, Springer;2010:35-53.
4. HATEMI G, SILMAN A, BANG D et al.: EULAR Expert Committee. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008; 67: 1656-62.
5. ARIDA A, FRAGIADAKI K, GIAVRI E, SFIKAKIS PP: Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011; 41: 61-70.
6. HANAUER SB, SANDBORN WJ, RUTGEERTS P et al.: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33.
7. SOYSAL T, SALIHOGLU A, ESATOGLU SN et al.: Bone marrow transplantation for Behçet's disease: a case report and systematic review of the literature. Rheumatology (Oxford). 2014; 53: 1136-41.
8. YASUI K, UCHIDA N, AKAZAWA Y et al.: Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease. Inflamm Bowel Dis 2008; 14: 396-400.
9. SAYARLIOGLU M, KOTAN MC, TOPCU N, BAYRAM I, ARSLANTURK H, GUL A: Treatment of recurrent perforating intestinal ulcers with thalidomide in Behçet's disease. Ann Pharmacother 2004; 38: 808-11.
10. BRIK R, SHAMALI H, BERGMAN R: Successful thalidomide treatment of severe infantile Behçet disease. Pediatr Dermatol 2001; 18: 143-5.
11. POSTEMA PT, den HAAN P, van HAGEN PM, BLANKENSTEIN M: Treatment of colitis in Behçet's disease with thalidomide. Eur J Gastroenterol Hepatol 1996 Sep; 8: 929-31. PubMed PMID: 8889464.Treatment of colitis in Behçet's disease with thalidomide. Eur J Gastroenterol Hepatol 1996; 8: 929-31.
12. LARSSON H: Treatment of severe colitis in Behçet's syndrome with thalidomide. J Intern Med 1990; 228: 405-7.
13. PATEY O, CHARASZ N, ROUCAYROL AM et al.: Thalidomide and ulcerative colitis in Behçet's disease. Gastroenterol Clin Biol 1989; 13: 104.
14. ROGé J, TESTAS P: Thalidomide and Behçet's syndrome. Gastroenterol Clin Biol 1984; 8: 196.
15. IDEGUCHI H, SUDA A, TAKENO M et al.: Gastrointestinal manifestations of Behçet's disease in Japan: a study of 43 patients. Rheumatol Int 2014; 34: 851-6.
16. TANAKA H, SHIMIZU N, TOUGASAKI E et al.: Successful treatment by azacitidine therapy of intestinal Behçet's disease associated with myelodysplastic syndrome. Int J Hematol 2013; 97: 520-4.
17. SHIMIZU Y, TAKEDA T, MATSUMOTO R et al.: Clinical efficacy of adalimumab for a postoperative marginal ulcer in gastrointestinal Behçet disease. Nihon Shokakibyo Gakkai Zasshi 2012; 109: 774-80.
18. TOYONAGA T, NAKASE H, MATSUURA M et al.: Refractoriness of intestinal Behçet's disease with myelodysplastic syndrome involving trisomy 8 to medical therapies-our case experience and review of the literature. Digestion 2013; 88: 217-21.
19. LI Y, HAN Z, WANG X et al.: Combination therapy of infliximab and thalidomide for refractory entero-Behçet's disease: a case report. BMC Gastroenterol 2013 9; 13: 167.
20. KINOSHITA H, KUNISAKI R, YAMAMOTO H et al.: Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication. Intern Med 2013; 52: 1855-62.
21. LEE JH, CHEON JH, JEON SW et al.: Efficacy of infliximab in intestinal Behçet's disease: a Korean multicenter retrospective study. Inflamm Bowel Dis 2013; 19: 1833-8.
22. MARUYAMA Y, HISAMATSU T, MATSUOKA K et al.: A case of intestinal Behçet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years. Intern Med 2012; 51: 2125-9.
23. WATANABE S, AIZAWA-YASHIRO T, TSURUGA K, KINJO M, ITO E, TANAKA H: A young girl with refractory intestinal Behçet's disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent. Rheumatol Int 2013; 33: 3105-8.
24. De CASSAN C, De VROEY B, DUSSAULT C, HACHULLA E, BUCHE S, COLOMBEL JF: Successful treatment with adalimumab in a familial case of gastrointestinal Behçet's disease. J Crohns Colitis 2011; 5: 364-8.
25. IWAMA I, KAGIMOTO S: Anti-tumor necrosis factor monoclonal antibody therapy for intestinal Behçet disease in an adolescent. J Pediatr Gastroenterol Nutr 2011; 53: 686-8.
26. IWATA S, SAITO K, YAMAOKA K et al.: Efficacy of combination therapy of anti-TNF-a antibody infliximab and methotrexate in refractory entero-Behçet's disease. Mod Rheumatol 2011; 21: 184-91.
27. KANEKO U, KISHI T, KIKUCHI M et al.: Two patients with childhood-onset Behçet's disease successfully treated by anti-tumor necrosis factor therapy. Nihon Rinsho Meneki Gakkai Kaishi 2010; 33: 157-61.
28. KWOK SK, JU JH, PARK KS et al.: Clinical Images: Entero-Behçet's disease. Arthritis Rheum 2010; 62: 1202.
29. ARIYACHAIPANICH A, BERKELHAMMER C, NICOLA H: Intestinal Behçet's disease: maintenance of remission with adalimumab monotherapy. Inflamm Bowel Dis 2009; 15: 1769-71.
30. NAGANUMA M, SAKURABA A, HISAMATSU T et al.: Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. Inflamm Bowel Dis 2008; 14: 1259-64.
31. UGRAS M, ERTEM D, CELIKEL C et al.: Infliximab as an alternative treatment for Behçet disease when other therapies fail. J Pediatr Gastroenterol Nutr 2008; 46: 212-5.
32. LEE JH, KIM TN, CHOI ST et al.: Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab). Korean J Intern Med 2007; 22: 24-7.
33. BYEON JS, CHOI EK, HEO NY et al.: Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case. Dis Colon Rectum 2007; 50: 672-6.
34. CHAWLA S, SMART CJ, MOOTS RJ: Recto-vaginal fistula: a refractory complication of Behçet's disease. Colorectal Dis 2007; 9: 667-8.
35. YüKSEL Z, SCHWEIZER JJ, MOURAD-BAARS PE et al.: A toddler with recurrent oral and genital ulcers. Clin Rheumatol 2007; 26: 969-70.
36. JU JH, KWOK SK, SEO SH et al.: Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab. Clin Rheumatol 2007; 26: 1383-5.
37. Van LAAR JA, MISSOTTEN T, van DAELE PL et al.: Adalimumab: a new modality for Behçet's disease? Ann Rheum Dis 2007; 66: 565-6.
38. YüCEL AE, KART-KöSEOGLU H, AKOVA YA et al.: Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behçet's disease. Rheumatology (Oxford) 2004; 43: 394-6.
39. KRAM MT, MAY LD, GOODMAN S et al.: Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 2003; 46: 118-21.
40. MUSSACK T, LANDAUER N, LADURNER R et al.: Successful treatment of cervical esophageal perforation in Behçet's disease with drainage operation and infliximab. Am J Gastroenterol 2003; 98: 703-4.
41. HASSARD PV, BINDER SW, NELSON V et al.: Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology 2001; 120: 995-9.
42. TRAVIS SP, CZAJKOWSKI M, McGOVERN DP et al.: Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001; 49: 725-8.
43. CASO F, COSTA L, RIGANTE D et al.: Biological treatments in Behçet's disease: beyond anti-TNF therapy. Mediators Inflamm 2014; 107421.
44. PINETON de CHAMBRUN M, WECHSLER B, GERI G, CACOUB P, SAADOUN D: New insights into the pathogenesis of Behçet's disease. Autoimmun Rev 2012; 11: 687-98.
45. YüKSEL S, EREN E, HATEMI G et al.: Novel NLRP3/cryopyrin mutations and pro-inflammatory cytokine profiles in Behçet's syndrome patients. Int Immunol 2014; 26: 71-81.
46. COMARMOND C, WECHSLER B, BODAGHI B, CACOUB P, SAADOUN D: Biotherapies in Behçet's disease. Autoimmun Rev 2014; 13: 762-9.
47. TRIOLO G, ACCARDO-PALUMBO A, DIELI F et al.: Vgamma9/Vdelta2 T lymphocytes in Italian patients with Behçet's disease: evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor beta1 expression in active disease. Arthritis Res Ther 2003; 5: 262-8.
48. ACCARDO-PALUMBO A, GIARDINA AR, CICCIA F et al.: Phenotype and functional changes of Vgamma9/Vdelta2 T lymphocytes in Behçet's disease and the effect of infliximab on Vgamma9/Vdelta2 T cell expansion, activation and cytotoxicity. Arthritis Res Ther 2010; 12: 109.
49. SAYGIN C, UZUNASLAN D, HATEMI G: Currently Used Biologic Agents in the Management of Behçet's syndrome. Curr Med Chem 2015; 22: 1976-85.
50. HAMURYUDAN V, MAT C, SAIP S et al.: Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 443-50.
51. LAZZERINI M, MARTELOSSI S, MAGAZZU G et al.: Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial. JAMA 2013 27; 310: 2164-73.
52. LAZZERINI M, MARTELOSSI S, MAGAZZU G et al.: Effect of Thalidomide on Clinical Remission in Children and Adolescents with Ulcerative Colitis Refractory to Other Immunosuppressives: Pilot Randomized Clinical Trial. Inflamm Bowel Dis 2015; 21: 1739-49.
53. FRANKS ME, MACPHERSON GR, FIGG WD: Thalidomide. Lancet 2004 29; 363: 1802-11.
54. BAUDITZ J, WEDEL S, LOCHS H: Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002; 50: 196-200.
55. HISAMATSU T, UENO F, MATSUMOTO T et al.: The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNF-a monoclonal antibodies. J Gastroenterol 2014; 49: 156-62.
56. HAMURYUDAN V, HATEMI G, TASCILAR K et al.: Prognosis of Behçet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial. Rheumatology (Oxford) 2010; 49: 173-7.
57. FURUTA S, CHOW YW, CHAUDHRY AN et al.: Switching of anti-TNF-a agents in Behçet's disease. Clin Exp Rheumatol 2012; 30: S62-8.